Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21516
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 733–744 of 21,516 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 1 Interventional

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NCT07226843
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Interventions
LY4584180, Rituximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001

NCT07867288
View directory record Official record
Conditions
Nonobstructive Hypertrophic Cardiomyopathy
Interventions
HTX-001
Drug
Lead sponsor
Haya Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Kansas City, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Active, not recruiting Not applicable Interventional

Healing Outcomes of Peri-implant Soft Tissues With Different Healing Abutments

NCT07249242
View directory record Official record
Conditions
Implant
Interventions
Healing Abutment- customized, Healing Abutment- pre fabricated
Device
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Recruiting Phase 1 Interventional

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions
Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Recruiting Phase 2 Interventional

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Recruiting Phase 3 Interventional

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1240
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 813 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

NCT04968184
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Placebo, KBP-5074
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501
View directory record Official record
Conditions
Hematologic Cancer
Interventions
ABBV-101
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Completed Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619
View directory record Official record
Conditions
Asthma
Interventions
Fp/ABS, FP, ABS, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
91
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Recruiting Phase 3 Interventional

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

NCT07393282
View directory record Official record
Conditions
High Risk Smoldering Multiple Myeloma (HR-SMM)
Interventions
Linvoseltamab, Daratumumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST
Completed Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

NCT06615557
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 1:58 PM EST